23268-03-3

Basic information

• Product Name: Butanedioic acid, methyl-, 4-methyl ester
• CAS NO: 23268-03-3
• Molecular Formula: C6H10O4
• Molecular Weight: 146.143
• Mol File: 23268-03-3.mol
• Article Data: 35

Chemical Properties

• CAS DataBase Reference: Butanedioic acid, methyl-, 4-methyl ester(CAS DataBase Reference)
• NIST Chemistry Reference: Butanedioic acid, methyl-, 4-methyl ester(23268-03-3)
• EPA Substance Registry System: Butanedioic acid, methyl-, 4-methyl ester(23268-03-3)

Safety Data

• Hazardous Substances Data: 23268-03-3(Hazardous Substances Data)

Usage

Description

Butanedioic acid, methyl-, 4-methyl ester, also known as dimethyl malonate, is a chemical compound that serves as a versatile building block in the synthesis of pharmaceuticals, agrochemicals, and fragrances. It is a clear, colorless liquid with a fruity odor, slightly soluble in water, and miscible in most organic solvents. Known for its reactivity and versatility, it is commonly used as an intermediate in the synthesis of various organic compounds.

Uses

Used in Pharmaceutical Industry:
Butanedioic acid, methyl-, 4-methyl ester is used as a key intermediate in the synthesis of various pharmaceutical compounds due to its reactivity and ability to form a wide range of organic molecules.
Used in Agrochemical Industry:
Butanedioic acid, methyl-, 4-methyl ester is used as a building block in the production of agrochemicals, contributing to the development of effective and sustainable solutions for agriculture.
Used in Fragrance Industry:
Butanedioic acid, methyl-, 4-methyl ester is used as a component in the creation of fragrances, taking advantage of its fruity odor and compatibility with other organic compounds.
Used in Organic Synthesis:
Butanedioic acid, methyl-, 4-methyl ester is used as a versatile intermediate in organic synthesis, enabling the formation of a diverse array of organic compounds for various applications.
It is important to handle and store Butanedioic acid, methyl-, 4-methyl ester with caution, as it is flammable and can be harmful if ingested, inhaled, or in contact with the skin.

Upstream product

• 71-23-8 propan-1-ol 
• 21307-96-0 methyl 2-methylsuccinate 
• 7338-27-4 4-methoxy-2-methylene-4-oxobutanoic acid 
• 22644-27-5 (R)-methylsuccinic acid dimethyl ester 
• 67-56-1 methanol 
• 97-65-4 2-methylenesuccinic acid 
• 623-43-8 crotonic acid methyl ester 
• 617-54-9 citraconic acid dimethyl ester 
• 498-23-7 citraconic acid 
• 143225-23-4 2(R)-Methyl-4-Benzyl Succinate 
• 3641-51-8 2-(R)-methylsuccinic acid 
• 498-21-5 2-methylbutanedioic acid 
• 4100-80-5 2-methylsuccinic anhydride 

Downstream Products

• 32980-34-0 2-benzyl-3-methyl-succinic acid 1-methyl ester 
• 1432125-13-7 methyl 4-(2-{4-[({2-[(3-{[(2-{[(2R)-4-methoxy-2-methyl-4-oxobutanoyl](methyl)amino}ethyl)(pentan-3-yl)amino]methyl}benzoyl)amino]-4,5,6,7-tetrahydro-1-benzothiophen-3-yl}carbonyl)amino]phenyl}ethyl)benzoate 
• 1384132-79-9 (R)-(5-bromo-3-methylpent-1-ynyl)benzene 
• 1174194-07-0 (R)-3-methyl-5-phenylpent-4-yn-1-ol 
• 1351949-97-7 C₃₂H₄₄N₆O₆ 
• 1351949-91-1 C₂₂H₃₁N₅O₄ 
• 1351949-75-1 C₂₉H₃₇N₃O₅ 
• 1351949-59-1 C₁₉H₂₄N₂O₃ 
• 1351948-95-2 C₃₂H₄₂N₆O₆ 
• 1351948-90-7 C₂₂H₂₉N₅O₄ 
• 1351949-30-8 C₃₂H₄₂N₆O₆ 

Relevant articles and documents

Application of Transition-Metal Catalysis, Biocatalysis, and Flow Chemistry as State-of-the-Art Technologies in the Synthesis of LCZ696

LCZ696 is a novel treatment for patients suffering from heart failure that combines the two active pharmaceutical ingredients sacubitril and valsartan in a single chemical compound. While valsartan is an established drug substance, a new manufacturing process suitable for large-scale commercial production had to be developed for sacubitril. The use of chemocatalysis, biocatalysis, and flow chemistry as state-of-the-art technologies allowed to efficiently build up the structure of sacubitril and achieve the defined performance targets.

CYCLIC PHOSPHATE SUBSTITUTED NUCLEOSIDE DERIVATIVES FOR THE TREATMENT OF LIVER DISEASES

The present invention relates to Compounds of Formula (I) or Formula (II) or a pharmaceutically acceptable salt, solvate or enantiomer thereof, wherein A, B, R1, R2, R3, R4, Q and V are as defined herein. The present invention also relates to pharmaceutical compositions comprising a Compound of Formula (I) or Formula (II) and to their use in therapy.

Spirobenzylamine-Phosphine, Preparation Method Therefor And Use Thereof

The present invention relates to a spirobenzylamine-phosphine, preparation method therefor and use thereof. The compound has a structure represented by formula (I), wherein n=0 to 3; R1, R2, R3, R4, R5, R6, R7, R8 and R9 having a value as defined in claim 1. Starting from the substituted 7-trifluoromesyloxy-7′-diarylphosphino-1,1′-spiro-dihydroindene, the compound is synthesized in a two-step or three-step reactions. The new spirobenzylamine-phosphine is complexed with an iridium precursor and is subjected to ion exchange, to give an Iridium/spirobenzylamine-phosphine complex comprising various anions. The spiro benzyl amine-phosphine/Iridium complex according to the present invention may be used for catalyzing asymmetry hydrogenation of a variety of alpha-substituted acrylic acids, has high activity and enantio-selectivity, and has a good prospect of industrialization.